1-4 of 4
Alexey Aleshin, MD MBA
Close
Sort by
Journal Articles

Correlating Clinical and Genomic Features with E x Vivo Drug Sensitivity in Patients with Myelodysplastic Syndromes and Related Myeloid Neoplasms

Michael A Spinner, MD, Steven A Schaffert, PhD, Alexey Aleshin, MD MBA, Marianne T Santaguida, PhD, Hiroomi Tada, MDPhD, Peter L. Greenberg
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-140095
Published: 2020
Journal Articles

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Michael A Spinner, Alexey Aleshin, MD MBA, Marianne A Santaguida, PhD, Steven A Schaffert, PhD, Taher Abbasi, MS, MBA, Jeffrey N Sanders, A Scott Patterson, MA, Diane Heiser, PhD, James L Zehnder, Peter L Greenberg, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4239.
https://doi.org/10.1182/blood-2019-129473
Published: 2019
Journal Articles

Single-Cell Mutational Profiling Describes the Molecular Heterogeneity of Clonal Evolution in MDS during Therapy and Relapse

Alexey Aleshin, MD MBA, Robert Durruthy-Durruthy, PhD, Bruno C. Medeiros, MD, Dennis J. Eastburn, PhD, Peter L Greenberg, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5503.
https://doi.org/10.1182/blood-2018-99-120368
Published: 2018
Journal Articles

Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse

Alexey Aleshin, MD MBA, Robert Durruthy-Durruthy, PhD, M. Ryan Corces, PhD, Melissa Stafford, Michaela Liedtke, MD, Bruno C. Medeiros, MD, Dennis J. Eastburn, PhD, Ravindra Majeti, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1469.
https://doi.org/10.1182/blood-2018-99-118089
Published: 2018